What is Zacks Small Cap’s Estimate for ORMP Q1 Earnings?

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) – Investment analysts at Zacks Small Cap issued their Q1 2025 earnings per share estimates for shares of Oramed Pharmaceuticals in a report issued on Thursday, April 3rd. Zacks Small Cap analyst M. Marin forecasts that the biotechnology company will post earnings of ($0.01) per share for the quarter. The consensus estimate for Oramed Pharmaceuticals’ current full-year earnings is ($0.03) per share. Zacks Small Cap also issued estimates for Oramed Pharmaceuticals’ Q2 2025 earnings at ($0.01) EPS, Q3 2025 earnings at ($0.01) EPS, Q4 2025 earnings at ($0.03) EPS and FY2025 earnings at ($0.07) EPS.

Oramed Pharmaceuticals (NASDAQ:ORMP) last posted its quarterly earnings results on Thursday, March 27th. The biotechnology company reported $0.01 EPS for the quarter, beating the consensus estimate of ($0.03) by $0.04.

Separately, StockNews.com downgraded shares of Oramed Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, February 19th.

Oramed Pharmaceuticals Stock Performance

Oramed Pharmaceuticals stock opened at $2.10 on Monday. The company has a market cap of $85.79 million, a P/E ratio of 19.09 and a beta of 1.50. Oramed Pharmaceuticals has a one year low of $1.96 and a one year high of $3.09. The business has a fifty day moving average of $2.28 and a two-hundred day moving average of $2.34.

Institutional Investors Weigh In On Oramed Pharmaceuticals

Several institutional investors have recently modified their holdings of the company. XTX Topco Ltd increased its stake in Oramed Pharmaceuticals by 59.7% in the 3rd quarter. XTX Topco Ltd now owns 24,716 shares of the biotechnology company’s stock valued at $60,000 after purchasing an additional 9,242 shares in the last quarter. Boothbay Fund Management LLC grew its holdings in Oramed Pharmaceuticals by 2.0% in the fourth quarter. Boothbay Fund Management LLC now owns 845,188 shares of the biotechnology company’s stock valued at $2,045,000 after purchasing an additional 16,857 shares during the last quarter. World Equity Group Inc. purchased a new position in shares of Oramed Pharmaceuticals in the fourth quarter valued at $48,000. Marquette Asset Management LLC acquired a new position in shares of Oramed Pharmaceuticals during the 4th quarter worth $81,000. Finally, Dimensional Fund Advisors LP raised its stake in shares of Oramed Pharmaceuticals by 143.8% during the 4th quarter. Dimensional Fund Advisors LP now owns 118,995 shares of the biotechnology company’s stock worth $288,000 after buying an additional 70,190 shares during the last quarter. Hedge funds and other institutional investors own 12.73% of the company’s stock.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.